gene_symbol
HLA-A
hgnc_id
HGNC:4931
binding_type
receptor ligand recognition
cytotoxicity
NO
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
The vaccine primes neoantigen-specific CD8+ T cells, which then recognize tumor cells presenting the neoantigen peptide on HLA-A and kill them via perforin/granzyme (and Fas–FasL) pathways; HLA-A expression alone is not targeted.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
On
gated
Off
other_modifier
Presents neoantigen peptides to CD8+ T cells
trial_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06751849
disease_id_num_tar_ref
5036
drug_id_num_tar_ref
13616